SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " fda " 2,420 found 🔀 AI-powered Shuffle
From media empires to crypto: the best business books to read this summer
Keza MacDonald’s Super Nintendo and Martin Sixsmith’s Suing the Kremlin are among these top reads
MSU's McCoy Biagioli makes history with second Michigan Amateur title
McCoy Biagioli, 20, of White Lake, beat Grand Blanc's Logan Price, 28, in the championship match Friday at Eagle Eye Golf & Banquet Center in Bath.
Could Your AI Content Land Your Business In Court?
Generative AI is helping businesses create content faster, but it is also creating new copyright and intellectual property risks that many companies do not understand.
LeBron James' birthplace urges NBA star, 'Come home...please'
Akron's Summa Health, birthplace of LeBron James, posted a not-so-subtle message on Instagram urging the NBA star to finish his career in Cleveland.
Donald Trump's Freedom 250 celebration suffers setback as falling panel nearly crushes dancers
Donald Trump's beleaguered Freedom 250 celebration suffered another potentially disastrous setback on Thursday, when a large panel on the White House main stage fell, nearly crushing a group of dancers.
Slimmed-down ESSENCE Fest lineup could ease delay issues
The annual festival, which has called New Orleans home for nearly three decades, is featuring performances from artists including Babyface and Cardi B, along with appearances from former First Lady Mi...
FDA clears AI-enabled CCTA plaque analysis tool from Keya Medical
The company now has multiple FDA-cleared algorithms for evaluating CCTA results.
Why the USMNT can't appeal Folarin Balogun's suspension after controversial World Cup red card
Cowboys Headlines: Laziest approach, rookie CB's opportunity, WR ranks
The Cowboys may not have shattered tradition this offseason, but looking at it as a failure is a weird take.
Why the USMNT can't appeal Folarin Balogun's suspension after his controversial World Cup red card
Red Wings Sign Depth Defenseman
The post Red Wings Sign Depth Defenseman appeared first on Detroit Hockey Now. The opening of the NHL’s 2026 Free Agency period has seen the league trying to round out their rosters with […] The post Red Wings Sign Depth Defenseman appeared first on Detroit Hockey Now.
'60 Minutes' shake-up continues with departure of longtime producer
The newsroom at "60 Minutes" is facing another goodbye. Henry Schuster, a longtime producer on the CBS program, revealed his departure in a LinkedIn post Monday, June 29.
FDA says Zyn can market its pouches as safer than cigarettes
The influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning Rounds
Servers recalled after glitch results in radiologists reading images for wrong patients
The issue could cause a reader to unintentionally report on the wrong patient when using interactive applications, according to a notice from the FDA.
RFK Jr. wants to make it easier to get peptides. FDA scientists disagree.
The health secretary has advocated for deregulating certain peptides, but FDA scientists point to a lack of data about their safety and effectiveness. Some have not been studied in humans.
FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports
Documents reviewing the research on peptides note lack of good evidence of efficacy or safety. Yet an FDA panel will consider easing access to them later this month.
FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports
Documents reviewing the research on peptides note lack of good evidence of efficacy or safety. Yet an FDA panel will consider easing access to them later this month.
New York cardiologist performs first procedure in US with FDA-cleared imaging tech
The OpusWave Dual Sensor Imaging captures both IVUS and OFDI, providing users with two complementary views of the coronaries at the same time.
Anthropic launches Claude Science in bid to expand revenue streams ahead of IPO
Anthropic is launching its Claude Science product as it seeks to increase revenue streams ahead of its anticipated initial public offering.
'Supergirl' is a decent standalone movie — so why is everyone acting like it’s awful?
'Supergirl' has been in theaters for less than a week, and it seems everyone is quick to call it a failure after a disappointing opening weekend at the box office. But does it actually deserve the backlash it's receiving?
Peptides are everywhere in health and beauty, but does the science actually back up the claims?
Peptides are everywhere — promising to fix wrinkles, weight gain, and even torn ligaments. But are they safe? The FDA is moving to expand access. Here's what a medical expert wants you to know. 👇
Exclusive: FDA allows ZYN to sell pouches on health benefits
The pouches can be marketed as less risky than cigarettes.
FDA digital leader hints at coming AI policy updates
Today's health tech news includes virtual PT for a whole country, what the FDA is considering on AI policy, and more
Crews called to overnight fire to auto repair business in Boonville
We’re told there was damage to the back corner of the business.
Crews called to overnight fire to auto repair business in Boonville
Crews called to overnight fire to auto repair business in Boonville
Crews called to overnight fire to auto repair business in Boonville
Crews called to overnight fire to auto repair business in Boonville
Crews called to overnight fire to auto repair business in Boonville
Crews called to overnight fire to auto repair business in Boonville
Half of states sue over Medicaid work requirements
FDA peptide panelists, a new study on Covid and flu shots, and more health news from Morning Rounds
Contributor: Mental health care isn't ready for psychedelic side effects
Accelerated FDA approval will invite recklessness. But don't block these important medications. Take steps to prepare.
FDA staff recommendation undercuts RFK Jr.’s push to expand peptides
The chains of amino acids are increasingly marketed for antiaging and health benefits. However, medical experts say many of those claims have not yet been fully tested.
AI cuts hospital system's MRI wait times by more than 50%
The health network, which operates 37 hospitals in California, drastically reduced scheduling delays after integrating an FDA-cleared algorithm designed to speed up imaging acquisition times.
Toronto Maple Leafs invite Matt Lahey to development camp
Michigan State sophomore Matt Lahey will be participating in the Toronto Maple Leafs development camp.
3-star receiver Darnell Jackson Jr. commits to Utah
The Utes received their third commitment of the day as three-star Texas wide receiver Darnell Jackson Jr. announced his pledge to Utah on Wednesday.
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of unapproved drugs popular with followers of Robert F. Kennedy Jr.
Weston Port, three-star LB, commits to Michigan football
Three-star linebacker Weston Port committed to U-M in the class of 2027 on Monday, June 29.
FDA approves surgical device for high-risk aortic procedures
The AMDS Hybrid Prosthesis was designed to help clinicians treat DeBakey Type 1 dissections complicated by malperfusion. It works as a complement to hemiarch replacement, preserving the native arch and making reinterventions possible if needed.
Alicia Keys cries, Springsteen speaks during emotional Clive Davis funeral
Bruce Springsteen, Alicia Keys and more stars are turning out to honor Clive Davis.
Bill Maher upstaged by Trump impersonator at Mark Twain Prize ceremony
Bill Maher might be getting a taste of his comedic karma.
IU Health opens one of nation's first FDA-cleared 3D-printing studios
It's changing how doctors work and talk to their patients.
Raveheart by Graeme Armstrong review – ravers rebel in a Scottish political satire
A veteran techno DJ embarks on a campaign of civil disobedience in this passionate and at times hilarious tale of underground resistance
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the FDA has no…
Got the tennis bug? How to play sport without paying
As the world's best players begin play at Wimbledon, how can you get into sport on a budget.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Iran Might Be The Unluckiest Sports Team Ever
After two late goals in another game sealed Iran’s fate, Team Melli was left to rue one of the most brutal exits in World Cup history.
Winner and Loser of the Week in Florida politics
FDACS moves fast on the mealybug threat, while Ye's Tampa concerts proceed despite pushback.
Everything we know about Taylor Swift and Travis Kelce’s wedding
NEW YORK — There are more people ostensibly invited to celebrate the love story of Taylor Swift and Travis Kelce than there are tidbits of publicly available information about the
Author Meg Cabot says she's read the 'Princess Diaries 3' script 'and it was amazing'
Meg Cabot, author of the 'Princess Diaries' book series, says she's read the script for 'The Princess Diaries 3' starring Anne Hathaway and it's 'amazing.'
Americans keep poisoning themselves with semaglutide, other weight loss drugs
These incidents became much more common after the FDA started approving GLP-1 drugs for chronic weight management in 2021.
Trump election bill fight brings House business to a halt
A Republican revolt over President Donald Trump's election overhaul bill has thrown the House into disarray.
Trump election bill fight brings House business to a halt
A Republican revolt over President Donald Trump's election overhaul bill has thrown the House into disarray.
Former Illinois forward Ben Humrichous signs contract with Nets
Heading to Brooklyn.
Travelers Championship brings business boost and traffic headaches for Cromwell-area shops
As golfers compete at the Travelers Championship, nearby restaurants and shops in the Cromwell area are seeing the tournament’s impact on business, with some owners welcoming the crowds and others pointing to traffic challenges.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
HOMETOWN ENTERTAINMENT: FloydFest 2026 Daydream
Organizers say FloydFest will feature Tedeschi Trucks Band, My Morning Jacket, Stephen Wilson Jr. and Lukas Nelson.
Emily Ratajkowski says she rejects the label 'divorced single mom'
Emily Ratajkowski is opening up about resenting the label "divorced single mom" following her split from ex-husband Sebastian Bear-McClard.
FDA's breakthrough pipeline fills up with generative AI devices
In this edition of STAT Health Tech: FDA drops enforcement against Whoop, more AI devices get FDA 'breakthrough' label, and more.
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.
Business Process Outsourcing & Consulting Stocks Q1 Teardown: Genpact (NYSE:G) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how business process outsourcing & consulting stocks fared in Q1, starting with Genpact (NYSE:G).
What Has Andy Burnham, Britain's Likely Next Prime Minister, Said About Trump?
If Burnham’s planned leadership bid remains unchallenged, he could replace Starmer in a matter of weeks and it will likely fall on him to heal the rift between Washington and Westminster.
Business bankruptcies down but closures and farm reorgs up
Between 2019 to 2026, 292 businesses in South Dakota filed for bankruptcy.
PENN Entertainment Celebrates Grand Opening of Hollywood Casino and Hotel Aurora
WYOMISSING, Pa. & AURORA, Ill., June 24, 2026--PENN Entertainment, Inc. (Nasdaq: PENN) ("PENN" or the "Company") today celebrates the grand opening of Hollywood Casino and Hotel Aurora, the all-new, $360 million state-of-the-art casino and hotel. PENN’s latest land-based property replaces the former riverboat property that operated on the Illinois shores of the Fox River since 1993.
What an abandoned heart failure trial says about 'breakthrough' devices that don’t reach patients
An abandoned heart-failure trial offers a rare window into devices that the FDA deems "breakthrough" but never reach patients.
Dartmouth Health reports $63.5 million loss at end of quarter
According to a recent filing, Dartmouth Health lost millions of dollars due to severe winter weather, inflation, and other challenges.
Colorado author shares straightforward tools for improving men's mental health
FDA drops enforcement against Whoop after it tweaks blood pressure feature
The FDA told wearable maker Whoop last week that it would not take further enforcement action over the company's blood pressure feature.
Spotlighting business in Culver City, with Culver & Main restaurant
FDA clears AI software for flagging signs of vascular disease
The newly cleared software alerts clinicians when it detects a suspected vascular occlusion.
Tight End U Year 6 and Beyond
Greg Olsen on Tight End University year six, youth sports, NFL turf debate, and broadcasters in front offices.
OpenEvidence will add FDA-cleared AI to detect heart disease
In this edition of STAT Health Tech: OpenEvidence adds AI to detect heart disease, and Cadence raises $100 million, and more.
A sweeping new AI to detect heart conditions is coming to OpenEvidence
EchoNext, a new AI tool cleared by the FDA, will let doctors use an EKG to easily screen patients for structural heart diseases.
Mamdani and AI Industry Flex Political Power in New York, Plus More to Watch in Tuesday's Primaries
WASHINGTON (AP) — Two opposing factions in the artificial intelligence industry square off in a Democratic primary for a U.S. House seat. New York City Mayor Zohran Mamdani tests his political clout by backing fellow democratic socialists. And President Donald Trump, after two of his chosen ...
Tucker Carlson says he will no longer support the Republican Party
The comments come two months after Carlson expressed regret for supporting President Donald Trump.
Health Brief: FDA signals reset in drug reviews
Plus: The data behind China’s biotech surge
Vikings have seen improvements from J.J. McCarthy this offseason
J.J. McCarthy is showing he can get better to the Vikings coaching staff ahead of training camp.
Health officials launch clinical trial reforms to counter China threat
The Food and Drug Administration (FDA) on Monday launched a new initiative to speed up early-stage clinical trials as part of an effort to reduce development timelines and reverse a growing trend o…
Man sells his couch on Facebook Marketplace. Then Zelle flags the payment for being too high. Then he learns he’s been bamboozled
“A little red flag is going off in my head."
FDA to launch pilot program to speed up early-stage clinical trials
Federal health officials aim to speed up drug development and better compete with China.
ImPACT Applications, Inc. adds UpRight Science Balance Assessment for Athletes
ImPACT Applications, Inc., the leader in concussion management tools, announced today that Balance by UpRight—an FDA-cleared balance measurement technology from UpRight Science—is now available through the ImPACT Platform.
1 in 3 Americans use chatbots for health advice. These 6 patients explain why.
They say cost, speed and other considerations drove them to AI. They are also learning what to believe and what to take with caution.
New Zealand vs Egypt Highlights
Check out the full game highlights between New Zealand and Egypt in the 2026 FIFA World Cup™. Announced by Mark Scott and Cobi Jones.
Former high-level health officials think out loud about HHS, FDA
More than 15 years after the National Academy of Medicine summoned a blue-ribbon panel to “reimagine” the Department of Health and Human Services for the 21st century, the cabinet-level operation has yet to make good on the experts’ overarching directive.
Stray Kids to drop new album in August, announces new world tour
Popular boy group Stray Kids will release a new album in August and embark on a new world tour, the group's agency JYP Entertainment said Monday. T...
Assessing Denzel Mims’ chances of making the 53-man roster
Do you think Denzel Mims has a chance to make the roster?
Japan takes massive leap in the World Cup Power Rankings
Japan crushed Tunisia in the 1,000th World Cup game ever played and are looking like a legitimate contender this summer.
Father's Day launch for male mental health campaign
ManDown wants to raise funds to create more meeting groups for men to attend in the UK.
‘A child goes to bed and doesn’t wake up’: the families left in shock after the sudden death of their healthy children
Sudden cardiac arrest is statistically rare but among the leading causes of death for children and young people. And families often have no idea of the risk until it’s too late
Wilton Simpson continues adding to re-election war chest despite weak competition
The egg farmer from Trilby flipped FDACS from blue to red four years ago.
Popular Kapahulu running shop to close after 50 years in business
Running Room has been a must-stop shop for runners for five decades.
For Vance, Iran talks could shape political rise
U.S. Vice President JD Vance is poised to take on his biggest role yet on the international stage as President Donald Trump's chief negotiator to end the three-month war with Iran, a moment that could shape Vance’s prospects as a White House successor.
Oakes Farms withdraws plans for new Bonita Springs entertainment complex
Oakes Farms has withdrawn its proposal to transform the old greyhound track in Bonita Springs into an entertainment complex.
ICO watchdog opens inquiry into cameras in mental health patients’ bedrooms
Exclusive: Oxevision system used by 40% of NHS mental health trusts being scrutinised by information commissioner over privacy concerns
New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
This could prevent thousands of hospitalizations.
Comic Carlos Mencia arrested on suspicion of felony tax evasion
Comedian Carlos Mencia, who broke out in the early 2000s with his Comedy Central series 'Mind of Mencia,' was arrested Thursday morning in Los Angeles on suspicion of a dozen felony tax evasion counts.
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada
CALGARY, Alberta, June 18, 2026--The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this role, she will lead 550+ employees working at multiple sites across Canada and serves as a member of Bayer’s North American Leadership Team for Crop Science.
Inside High 5: Renderings of Estero’s upcoming entertainment complex
See new renderings of High 5 Entertainment in Estero, including bowling, arcade attractions, pickleball courts, miniature golf, dining areas and outdoor gathering spaces ahead of its planned 2027 opening.